Pfizer Q4 FY17 results (Jan–Mar 2017) and concall

Pfizer India faced a perfect storm in FY17, navigating a ₹450-500 crore revenue hit from the Corex FDC ban, NLEM price reductions, and portfolio divestments. Despite these headwinds, the company maintained stable gross margins and saw double-digit growth in its core non-regulated brands like Prevenar 13. Management is now focused on a 'rebased' growth strategy, leveraging the new Meronem distribution deal and Corex line extensions to recover lost volumes within a year.